Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy-Reference-Cited by-同舟云学术

Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy

Published:2022-05-11 Issue:6 Volume:6 Page:e716
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Laribi Kamel,Baugier de Materre Alix,Ghez David,Dartigeas Caroline,Tomowiak Cécile,Mahé Béatrice,Micol Jean-Baptiste,Merabet Fatiha,Leprêtre Stéphane,Herbaux Charles,Ysebaert Loïc,Le Calloch Ronan,Willems Lise,Voldoire Maud,Roos-Weil Damien,Bravetti Clotilde,Touileb Yamina,Davi Frédéric,Nguyen-Khac Florence,Maloum Karim,Béné Marie C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference9 articles.

1. Perturbation of the normal immune system in patients with CLL.;Forconi;Blood,2015

2. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.;Tsimberidou;J Clin Oncol,2009

4. Incidence of therapy-related myeloid neoplasia afte or initial therapy for chronic lymphocytic leukemia or with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.;Smith;Blood,2011

5. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.;Benjamini;Leuk Lymphoma,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL;Blood Advances;2024-02-14

2. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up;Blood;2023-11-23

3. Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06);The Korean Journal of Internal Medicine;2023-09-01

4. Cyclophosphamide/fludarabine;Reactions Weekly;2022-12-03